TNFRSF13B variants have been reported in patients with MDS11, Hodgkin lymphoma56, and have been shown to be associated with chronic lymphocytic leukemia risk57 and multiple myeloma risk58. This evidence concerns the gene TNFRSF13B and plasma cell myeloma.